Table 4 Safety and laboratory data after baricitinib or tofacitinib treatment (1–6 months)

Safety data

Any adverse event after the start of therapy, n (%)

25 (33.8%)

46 (43.8%)

0.18

Adverse event resulted in discontinuation of treatment, n (%)

3 (4.1%)

5 (4.8%)

0.82

Infection, n (%)

7 (9.5%)

12 (11.4%)

0.67

Herpes zoster, n (%)

3 (4.1%)

4 (3.8%)

0.93

Leukopenia

1 (1.4%)

7 (6.7%)

0.09

Increasing CREA

0

3 (2.86%)

0.14

Increasing ALT/AST

10 (13.51%)

15 (14.29%)

0.88

Cancer, n (%)

0

0

1.00

Major adverse cardiovascular event, n (%)

1 (1.35%)

0

0.23

Venous thromboembolism, n (%)

0

0

1.00

Laboratory data—median change from baseline

WBC (×10⁹/L)

-0.9**

-0.7**

0.55

HGB (g/L)

4.0

6.5*

0.18

PLT (×10⁹/L)

-0.6

-70.7**

0.001

NEU (×10⁹/L)

-1.1**

-0.95**

0.56

LYM (×10⁹/L)

-0.2

-0.12

0.51

AST (U/L)

3.0*

3.0**

0.59

ALT (U/L)

4.0*

4.0**

0.77

CREA (µmol/L)

2.0

4.0

0.11

Glucocorticoid dosage (mg) after 1 month

2(0–4)

0(0–4)

0.21

Glucocorticoid dosage(mg) after 6 months

0(0–2)

0(0–2)

0.71